R21: Cancer Therapeutics-A – ATC (82)
The Cancer Therapeutics A special emphasis panel focuses on investigating the mechanisms-of-action of advanced cancer therapeutics across drug classes, and their combinations, in the treatment of human cancer. Studies focus on cellular and in vivo activity studies, including investigations of resistance and toxicity.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Mechanism of action of established or repurposed cancer therapeutics (previously tested in model organisms and/or humans), spanning small molecule, peptide, protein, cellular, and genetic experimental therapeutics.
- Mechanisms of resistance to established cancer therapeutics and strategies to circumvent intrinsic and extrinsic resistance mechanisms, including genetic and chemical screens.
- Identification and validation of combination therapies to maximize the efficacy of cancer treatments including rational combinations of conventional and targeted therapies with novel agents.
- Studies of cellular pharmacokinetics and pharmacodynamics of cancer therapeutic agents and the impact of drug properties on anti-cancer drug function.
